- Cash are down 40% Y/Y, 0 long term assets, Operating income down 6.39% the list seems to go on and on.
- So what makes this a potential investment opportunity after their latest cash raise?
- Phase one Clinical study showed safety and tolerability of AT-301 a potential useful tool in the fight against the ongoing Covid crisis.
With the markets at all time highs where will a retail investor find the next trade possibly right here. If one can look past the balance sheet here they might able to see the potential for decent gains coming into the 2nd or 3rd Q of 2021. After the recent cash raise there will be about 8 months of burn rate left before there is cause for refilling the boosters on this stock. This gives the average retail investor time to decide their investing fate or take the leap. My self personally I am constantly watching this company tracking the stock price and have made a few trades previous to the recent cash raise which is why for myself this is becoming more attractive by the day...
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.